Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.25
Bid: 14.00
Ask: 14.50
Change: 0.00 (0.00%)
Spread: 0.50 (3.571%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 14.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Re US Venture -- Aberro

17 Nov 2005 07:02

Angle PLC17 November 2005 For Immediate Release 17 November 2005 ANGLE PLC US VENTURE, ABERRO: PRODUCT IN BETA TRIALS ANGLE is delighted to announce that it has officially launched Aberro, asoftware testing company (formerly known as ContraSoft). Aberro is 57 per cent.owned by ANGLE and is ANGLE's first US venture founded since ANGLE's flotationin 2004. Aberro has developed a beta release of its product, AberroTest, which is in useat several companies. The product solves a number of issues in the softwareindustry and is expected to be released commercially later this year. Aberro ispreviewing the technology at STARWEST, the world's largest software testingevent, which is being held this week in Anaheim, California. A recent IDC report projected that in 2006, companies will spend over $1 billionon tools to help improve their software testing capabilities. Aberro's AdaptiveAutomated Testing delivers easy and rapid test creation, with no programmingskills required, coupled with low-cost execution that automatically adapts tochanges in the target application. With Aberro's technology, tests areautomatically created in a matter of minutes. This allows testers to find andrepair defects sooner and more easily, while reducing development costs andimproving overall software quality. In developing Aberro, ANGLE has assembled an experienced management team headedby CEO Douglas Smith and Vice President of Marketing Steve Lafferty. Smithjoined the company from ANGLE, where he served as an Entrepreneur in Residence.He has over 20 years of management experience, including CEO and COO roles atthree start-up companies and senior management positions at Digital Equipment,Compaq and EMC. Lafferty previously served as Business Unit Director withManugistics and has held senior-level marketing roles at Cadre, Iona, SterlingSoftware and Green Hills Software. Additionally, Aberro's Co-Founder and CTO William Rogers, Ph.D., brings over 20years of research and development experience to the team. Rogers was theoriginator of Aberro's revolutionary software testing technique, AdaptiveAutomated Testing, which enables rigorous automated testing of software farearlier than any other solution on the market. Rob Kornblum, Managing Director of ANGLE Ventures (US) said: "We are delighted with our progress at Aberro in delivering product to betausers so rapidly. We already see a tremendous amount of interest in Aberro'sproducts from the software community." For more information: ANGLE plc 01483 295830 Andrew Newland, Group CEO Buchanan Communications 020 7466 5000 Richard Darby, Suzanne Brocks, James Strong Notes to Editors Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE is listed on AIM (AGL.L)and operates from offices in the UK, the US and the Middle East. Further information can be found on www.ANGLEplc.com For more information on Aberro, please visit www.aberrosoftware.com or contactSteve Lafferty at 240.715 3333 x208. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
12th Apr 20217:00 amRNSANGLE's Parsortix system showcased at AACR 2021
30th Mar 20217:00 amRNSGlobal launch of clinical services laboratories
4th Mar 20217:00 amRNSUpdate on submission for FDA clearance
18th Feb 20217:00 amRNSParsortix-harvested CTCs uncover novel biomarker
8th Feb 20217:00 amRNSParsortix: Dynamic assessment of patient response
29th Jan 20217:00 amRNSParsortix demonstrates high capture rate of CTCs
26th Jan 20211:00 pmRNSHolding(s) in Company
20th Jan 20217:00 amRNSResearch confirms high performance of Parsortix
12th Jan 20217:00 amRNSChange of Auditor
5th Jan 20217:00 amRNSIssue of Equity
9th Dec 20207:00 amRNSParsortix can capture single cancer cell in sample
20th Nov 20204:18 pmRNSHolding(s) in Company
18th Nov 20204:51 pmRNSHolding(s) in Company
13th Nov 202010:46 amRNSResult of General Meeting
3rd Nov 20202:54 pmRNSDirector/PDMR Shareholding
29th Oct 20207:00 amRNSInterim Results
27th Oct 20206:28 pmRNSResult of Placing & Notice of General Meeting
27th Oct 20207:00 amRNSAccelerated bookbuild to raise up to £20m
20th Oct 20207:00 amRNSSubmission accepted by FDA for substantive review
28th Sep 20207:00 amRNSIssue of LTIP Options and Share Options
28th Sep 20207:00 amRNSANGLE announces completion of FDA submission
23rd Sep 20207:00 amRNSPotential treatment strategy to limit metastasis
11th Sep 20203:35 pmRNSHolding(s) in Company
11th Sep 20203:30 pmRNSHolding(s) in Company
2nd Sep 20201:49 pmRNSNotification of Interim Results and Webcast
2nd Sep 202010:00 amRNSHolding(s) in Company
27th Aug 20203:13 pmRNSResult of 2020 Annual General Meeting
18th Aug 20209:30 amRNSHolding(s) in Company
14th Aug 20207:00 amRNSParsortix use to assess response to immunotherapy
6th Aug 202012:20 pmRNSHolding(s) in Company
5th Aug 20207:00 amRNSNotice of AGM and Posting of Annual Report
20th Jul 20207:00 amRNSStudy: Parsortix use in metastatic breast cancer
8th Jul 20205:35 pmRNSHolding(s) in Company
8th Jul 20205:30 pmRNSHolding(s) in Company
8th Jul 20205:30 pmRNSHolding(s) in Company
25th Jun 20207:00 amRNSPreliminary Results
22nd Jun 20207:00 amRNSBlood donations recommenced for FDA studies
29th May 20207:00 amRNSNotice of Results
12th May 20207:00 amRNSCTC potential as biomarker in MET inhibitor trials
4th May 20207:00 amRNSLeading cancer centre publishes Parsortix workflow
28th Apr 20207:00 amRNSBusiness Update
17th Apr 20207:00 amRNSParsortix performance in head and neck cancer
3rd Mar 20207:00 amRNSAssessing risk of brain metastasis in lung cancer
27th Feb 20207:00 amRNSParsortix outperforms other CTC systems in RCC
25th Feb 20207:00 amRNSANGLE announce Tri-Con presentation with BioView
17th Feb 20207:00 amRNSData demonstrates key advantages of Parsortix
11th Feb 20207:00 amRNSStudy demonstrates Parsortix potential in melanoma
3rd Feb 20209:10 amRNSIssue of Equity
30th Jan 20207:00 amRNSInterim Results
30th Jan 20207:00 amRNSChange of accounting reference date

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.